Mandate

Vinge advises Oy Karl Fazer Ab

June 16, 2008

Vinge advises Oy Karl Fazer Ab (“Fazer”) in connection with the contemplated de-merger of Cloetta Fazer AB (publ) (“Cloetta Fazer”) that was announced in a press release today. Through the de-merger, Cloetta Fazer creates the two future companies Cloetta and Fazer Confectionery. The new Cloetta intends to apply for a listing on the OMX Nordic Exchange Stockholm. Fazer Confectionery, i.e. the remaining Cloetta Fazer, will be consolidated in the privately held Fazer Group.

The de-merger will be carried out in several steps. Initially, the new Cloetta will be distributed as dividend to the shareholders in Cloetta Fazer. The distribution of shares as dividend is carried out according to the so-called Lex ASEA rules.

Furthermore, Fazer announces a public offer to the shareholders of the remaining Cloetta Fazer. The offer consists of a cash part of SEK 202 and 0.92 shares of class B in the new Cloetta for each share in Cloetta Fazer, which upon full acceptance in the Offer represents a consideration of in total approximately SEK 2.5 billion and approximately 11.5 million shares of class B in the new Cloetta. The intention is to successfully complete the de-merger by January 2009.

The partners Göran Nyström, Fredrik Dahl and Mattias Schömer together with the associates Dain Nevonen and Emil Hedberg advise Fazer in connection with the de-merger of the current Cloetta Fazer and the public offer to the shareholders in the remaining Cloetta Fazer.

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025